Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 147Cholangiocarcinoma 26Liver Neoplasms 17Stomach Neoplasms 13Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 7Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Esophageal Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma 3Advanced Biliary Tract Cancer 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Glandular and Epithelial 2Melanoma 2Hepatitis B 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms Immunotherapy 2Uterine Cervical Neoplasms 1

Interventions

trebananib 1pembrolizumab 1lenvatinib 1camrelizumab 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Hepatocellular Carcinoma × lenvatinib × Gastrointestinal × Clear all
NCT05592197 2023-02-16

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Sun Yat-sen University

Phase NA Withdrawn
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡